Induction of HER2-specific cellular immunity after trastuzumab therapy
| Project/Area Number |
21791248
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Mie University |
|---|
Principal Investigator |
SAITO Kanako Mie University, 医学部附属病院, 助教 (90447871)
|
|---|
| Project Period (FY) |
2009 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2009: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Keywords | HER2 / トラスツズマブ / CTL / HER2陽性CD8陽性T細胞 / HER2特異的CD8+T細胞 |
|---|
| Research Abstract |
We have investigated whether HER2-specific cellular immunity could be induced after trastuzumab therapy in HER2-positive breast cancer patients. We analyzed the induction of HER2 specific CD8+T cells before and after trastuzumab therapy by tetramer assay and ELISPOT assay. HER2p369 specific CD8+T cells after trastuzumab were detected in only HER2-positive metastatic breast cancer patients. We could not detect HER2-specific CD8+T cells in early breast cancer patients after trastuzumab.
|
Report
(3 results)
Research Products
(11 results)
